Table 1.
Characteristics of patients with WES of tumor and normal tissue.
| All study patients | WES patients (n = 39) | T790Mpos (n = 25) | T790Mneg (n = 14) | p value |
|---|---|---|---|---|
| Age, median (IQR) | 66 (56–75) | 66 (54–75) | 62 (58–75) | 0.86 |
| Sex, female, n (%) | 29 (74) | 19 (76) | 10 (71) | 0.75 |
| ECOG PS 0/1, n | 20/19 | 14/11 | 6/8 | 0.43 |
| Never/light smokers, n (%) | 27 (69) | 19 (76) | 8 (57) | 0.22 |
| Stage IV at initial diagnosis, n (%) | 29 (74) | 17 (68) | 12 (86) | 0.22 |
| Brain metastases, n (%) | 10 (26) | 6 (24) | 4 (29) | 0.74 |
| EGFRmut: del19/L858R/other, n | 28/9/2 | 21/3/1 | 7/6/1 | 0.07 |
| TP53 mutated/wild type | 16/23 | 12/13 | 9/5 | 0.25 |
| PFS of 1L EGFR TKI, median (IQR), mo | 12.1 (8.6–25.5) | 13.6 (9.4–25.5) | 9.2 (5.8–18.7) | 0.70 |
| OS, median (IQR) | 33.7 (16.7–65.5) | 38.7 (17.8–60.5) | 23.3 (15.4–76.4) | 0.69 |
1L, first line; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; mo, months; n, number.